2022 is starting on a worrisome note; patience warranted
12/01/22 -"Philips ended 2021 on a soft note, with Q4 sales c.5% behind our expectations. Although full-year margin erosion was less severe than expected, management’s acknowledgement of supply challenges and ..."
Pages
69
Language
English
Published on
12/01/22
You may also be interested by these reports :
12/09/25
DiaSorin appears to be making significant progress in the testing space. The launch of speciality tests, introduction of the Plex platform, and ...
05/09/25
Bastide reported FY24/25 revenue in line with guidance and our forecast. The more technical business activities remain the primary driver of organic ...
05/09/25
Since we last pushed Philips’ (Buy; Netherlands) investment case in January 2024, its share price performance has been glaringly ahead of the MedTech ...
04/09/25
bioMerieux’s H1 profitability surpassed expectations. Topline growth was driven by robust performance across both segments. However, weakness in ...